Familial hypercholesterolaemia
KEYWORDS: people, diagnosis, quality, statement, data, treatment, testing, clinical, children, specialist, hypercholesterolaemia, familial hypercholesterolaemia, clinical diagnosis, familial, source

FH are assessed for lipid-modifying drug treatment by a specialist with expertise in FH in a child-focused setting by the age of 10 years. Data source: Local data collection. Process Proportion of children with FH who are assessed for lipid-modifying drug treatment by a specialist with expertise in FH in a child-focused setting by the age of 10 years. Numerator – The number of people in the denominator assessed for lipid-modifying drug treatment by a specialist with expertise in FH in a child-focused setting. Denominator – The number of children with FH aged 10 years. Data source: Local data collection. What the quality statement means for different audiences Service providers ensure that systems are in place for children with FH to be assessed for lipid-modifying drug treatment by a specialist with expertise in FH in a child-focused setting by the age of 10 years. Specialists with expertise in FH in children and young people assess children with FH for lipid-modifying drug treatment in a child-focused setting by the age of 10 years. Commissioners ensure that they commission services in which specialists with expertise in FH assess children with FH for lipid-modifying drug treatment, in a child-focused setting, by the age
